Oncogenic KRAS point mutations lead to the permanent activation of KRAS-dependent pathways and have been identified in multiple types of cancer, most notably in pancreatic cancer, non-small cell lung cancer (NSCLC), and CRC [7,8]. This evidence concerns the gene KRAS and colorectal carcinoma.